MedTrace Logo

Mass Balance Study of [14C]LC350189 in Healthy Volunteers

NCT04070846 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-06-26

No results posted yet for this study

Summary

This is a Phase 1, open-label, single-dose, mass balance study designed to evaluate the absorption, metabolism, and excretion of \[14C\] radiolabeled LC350189 after oral administration.

Conditions

  • Gout
  • Hyperuricemia

Interventions

DRUG

[14C] LC350189

Carbon-14 labelded LC350189

Sponsors & Collaborators

  • LG Chem

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-26
Primary Completion
2020-03-07
Completion
2020-03-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04070846 on ClinicalTrials.gov